Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19
Lucile P A Neyton,Ravi K Patel,Aartik Sarma,UCSF COMET Consortium,Andrew Willmore,Sidney C Haller,Kirsten N Kangelaris,Walter L Eckalbar,David J Erle,Matthew F Krummel,Carolyn M Hendrickson,Prescott G Woodruff,Charles R Langelier,Carolyn S Calfee,Gabriela K Fragiadakis,K Mark Ansel,Stephanie Christenson,Michael Adkisson,Walter Eckalbar,Lenka Maliskova,Andrew Schroeder,Raymund Bueno,Gracie Gordon,George Hartoularos,Divya Kushnoor,David Lee,Elizabeth McCarthy,Anton Ogorodnikov,Matthew Spitzer,Kamir Hiam,Yun S Song,Yang Sun,Erden Tumurbaatar,Monique van der Wijst,Alexander Whatley,Chayse Jones,Saharai Caldera,Catherine DeVoe,Paula Hayakawa Serpa,Christina Love,Eran Mick,Maira Phelps,Alexandra Tsitsiklis,Carolyn Leroux,Sadeed Rashid,Nicklaus Rodriguez,Kevin Tang,Luz Torres Altamirano,Aleksandra Leligdowicz,Michael Matthay,Michael Wilson,Jimmie Ye,Suzanna Chak,Rajani Ghale,Alejandra Jauregui,Deanna Lee,Viet Nguyen,Austin Sigman,Saurabh Asthana,Zachary Collins,Ravi Patel,Arjun Rao,Bushra Samad,Cole Shaw,Tasha Lea,Alyssa Ward,Norman Jones,Jeff Milush,Vincent Chan,Nayvin Chew,Alexis Combes,Tristan Courau,Kenneth Hu,Billy Huang,Nitasha Kumar,Salman Mahboob,Priscila Muñoz-Sandoval,Randy Parada,Gabriella Reeder,Alan Shen,Jessica Tsui,Shoshana Zha,Wandi S Zhu
DOI: https://doi.org/10.1038/s41467-024-49756-2
2024-06-28
Abstract:Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk and single-cell RNA sequencing of samples from the lower respiratory tract and blood, and assess plasma cytokine profiling to study the effects of dexamethasone on both systemic and pulmonary immune cell compartments. In blood samples, dexamethasone is associated with decreased expression of genes associated with T cell activation, including TNFSFR4 and IL21R. We also identify decreased expression of several immune pathways, including major histocompatibility complex-II signaling, selectin P ligand signaling, and T cell recruitment by intercellular adhesion molecule and integrin activation, suggesting these are potential mechanisms of the therapeutic benefit of steroids in COVID-19. We identify additional compartment- and cell- specific differences in the effect of dexamethasone that are reproducible in publicly available datasets, including steroid-resistant interferon pathway expression in the respiratory tract, which may be additional therapeutic targets. In summary, we demonstrate compartment-specific effects of dexamethasone in critically ill COVID-19 patients, providing mechanistic insights with potential therapeutic relevance. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.